Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series.
Hiren Mandaliya(Lake Macquarie Private Hospital), Fiona Day(Calvary Mater Newcastle Hospital), Adeeb Majid(Calvary Mater Newcastle Hospital), Jarad Martin(Calvary Mater Newcastle Hospital), Kalpesh Shah(John Hunter Hospital), James Lynam, Stephen P. Ackland(Mater Misericordiae Hospital), Girish Mallesara(Calvary Mater Newcastle Hospital), Stephen Philcox(John Hunter Hospital), Swetha Sridharan(Calvary Mater Newcastle Hospital), Tony Bonaventura(St Vincent’s Private Hospital Sydney), Mahesh Kumar(Calvary Mater Newcastle Hospital), André van der Westhuizen(Hunter Medical Research Institute), Stanley Chen(John Hunter Hospital), Michael Fay(Calvary Mater Newcastle Hospital), Jon Gani(John Hunter Hospital)
Cited by 0
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392